PHASE-II TRIAL OF IV 6-THIOGUANINE IN ADVANCED COLORECTAL-CARCINOMA

Google Scholar
  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (9-10) , 909-910
Abstract
Oral 6-thioguanine (6-TG) is an S-phase antimetabolite with significant activity against acute leukemia. Preliminary reports of activity of i.v. 6-TG indicated significant activity against advanced colorectal cancer. A phase II study of i.v. 6-TG in 29 patients with advanced measurable colorectal cancer was conducted. Only 1 transient partial response occurred. Toxic effects included mild myelosuppression, nausea, vomiting and minor ECG changes. Further use of i.v. 6-TG in the dose and schedule used to treat advanced colorectal cancer in this study is discouraged.

This publication has 1 reference indexed in Scilit: